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Tuberculosis (TB) remains as a global public health problem. In recent years, experimental
evidence suggesting the relevance of in vitro pellicle (a type of biofilm formed
at the air-liquid interface) production as a phenotype mimicking aspects found by
Mycobacterium tuberculosis-complex bacteria during in vivo infection has started to
accumulate. There are still opportunities for better diagnostic tools, therapeutic molecules
as well as new vaccine candidates to assist in TB control programs worldwide and
particularly in less developed nations. Regarding vaccines, despite the availability of a live,
attenuated strain (Mycobacterium bovis BCG) since almost a century ago, its variable
efficacy and lack of protection against pulmonary and latent disease has prompted
basic and applied research leading to preclinical and clinical evaluation of up to 15 new
candidates. In this work, I present examples of vaccines based on whole cells grown as
biofilms, or specific proteins expressed under such condition, and the effect they have
shown in relevant animal models or directly in the natural host. I also discuss why it might
be worthwhile to explore these approaches, for constructing and developing new vaccine
candidates for testing their efficacy against TB.
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INTRODUCTION
Since its introduction in 1921,Mycobacterium bovis BCG has been used to immunize around three
billion people worldwide, with close to 115 million new doses applied each year (Andersen and
Doherty, 2005; Skeiky and Sadoff, 2006), which have proven to be effective in protecting against
severe, disseminated forms of tuberculosis (TB). Despite this success, opportunities to improve this
vaccine are still evident, as this does not protect against the establishment of pulmonary infection
nor latent disease. Bacteria living within a structure comprising metabolically and phenotypically
diverse cells, covered by an extracellular matrix are often termed biofilms and compared to free-
living (planktonic) cells have been shown to be more tolerant to drug treatment, induce different
immune response and persist longer within infected tissues in vivo (Ojha et al., 2008). Considering
that tuberculosis is characterized for chronicity of infection, as well as the known need of prolonged
multiple antibiotic treatment to manage TB, even in drug-susceptible cases, it has been proposed
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that mycobacterial biofilms, where bacteria grow to produce
a thick aggregate of mycolic acids at the air-liquid interface
and exhibit increased phenotypic resistance to antibiotics(Ojha
et al., 2008), might mimic aspects found during in vivo infection
(Flores-Valdez et al., 2015), and that perhaps drug-persisters
found in Guinea pigs might constitute some sort of biofilm
(Orme, 2014).
Here, I present evidence of how using bacteria adapted to
grow as biofilms or components derived from it, constitute
effective preventive measures against some infectious diseases,
either in relevant animal models or within the natural host. These
were obtained from Pubmed using “biofilm vaccine” as keyword
(295 records published on November 5, 2015), and selecting
only original research papers showing evidence of evaluation of
efficacy vs. in vivo challenge. Finally, I propose the use of a similar
strategy to develop new TB vaccine candidates.
VACCINES BASED ON WHOLE CELLS
WITH ALTERED CAPACITY TO PRODUCE
BIOFILMS
Staphyloccocus aureus is a Gram-positive pathogen well-known
to produce biofilms, which are relevant in medical-device
associated infections in humans, as well as in mastitis produced
in animals. Using in vitro subculture of weak biofilm producer
strains to obtain strong biofilm producer bacteria, it was found
that the latter strains were more able to induce antibodies
vs. poly-N-acetyl-β-1,6-glucosamine (PNAG), which ultimately
led to better control of mastitis in sheep (Perez et al., 2009).
Perhaps PNAG production was not the only factor altered during
adaptation from weak to strong biofilm production, leading to
better control of infection, however this study showed the use of
biofilm-grown S. aureus to protect against infection. Similarly, S.
aureus cultured as biofilm improved protection vs. mastitis in a
mice model (Gogoi-Tiwari et al., 2015) compared to planktonic
cells.
On the other hand, a UDP-glucose dehydrogenase deletion
mutant of Edwardsiella tarda, showed increased autoaggregation
and biofilm production, reduced survival in macrophages and
reduced LD50 with increased survival in zebrafish, along with a
dose-dependent protection of turbot vs. a lethal challenge (Lv
et al., 2012). For another fish pathogen, Aeromonas hydrophila,
incorporation of heat-inactivated, biofilm-cultured bacteria into
the diet of catfish, promoted survival of 90–100% of vaccinated
and then infected fish vs. a 30–40% protection conferred by a
vaccine comprised of planktonic cells (Nayak et al., 2004), where
improvement was suggested to depend on a modification of LPS
in biofilm-grown cells (Asha et al., 2004), although the effect of
changes found in proteins on vaccine efficacy was not evaluated
in either study. Similar improved protection of biofilm-derived
vaccine was also found against A. hydrophila for the snakehead
murrel (Chana striata; Siriyappagouder et al., 2014).
Taken together, these studies demonstrate that there is
enhanced protection against virulence challenge for several
pathogens in their natural hosts or relevant animal models when
biofilm-grown cells are used as vaccines.
VACCINES BASED ON MIXED
COMPONENTS OBTAINED FROM
BIOFILMS
Another source of vaccine candidates are particular fractions
obtained from cells or culture filtrates or a mixture of variable
complexity composed of secreted proteins. In this regard, the
utilization of extracellular proteins found within the biofilm
matrix of S. aureus reduced the number of bacterial cells found
inside a biofilm and surrounding tissue in a model of mesh-
associated infection, as well as limited organ colonization upon
dispersion of pathogen from biofilm (Gil et al., 2014).
In a somewhat opposed manner, Bordetella pertussis biofilm-
derived membrane proteins protected against lung colonization
in mice, although at levels lower than those produced by
acellular pertussis vaccine currently in use, which is derived from
planktonic cultures (de Gouw et al., 2014). It would be interesting
to test particular components of each vaccine to compare their
efficacy, or add biofilm-exclusive antigens to vaccines already in
use to see if they can improve long-term protection, which was
the aim of analyzing biofilm extracts in the study by de Gouw
et al. (2014).
VACCINES BASED ON SPECIFIC
PROTEINS PRODUCED DURING BIOFILM
GROWTH
When specific antigens show the capacity to induce a protective
immune response, they can be used as subunit vaccines,
employed in order to reduce harmful side effects produced by
whole-cell products. A recombinant form of Biofilm associated
protein (Bap) from Acinetobacter baumannii was able to induce
production of specific antibodies, to reduce bacterial replication
in liver and spleen of mice infected intraperitonialy, which
succumbed 24 h post-infection when not immunized (Fattahian
et al., 2011). Moreover, in another study, the use of recombinant
Bap in combination with either Outer Membrane Vesicles
derived from an A. baumannii strain devoid of 3-O-linked acyl
chain from the disaccharide backbone of lipid A, or Outer
Membrane Protein A, reduced bacterial replication in spleen and
protected against death of infected mice (Badmasti et al., 2015).
On the other hand, a fragment obtained from S. epidermidis
surface exposed protein C (SseC) when used as subunit vaccine,
induced an immune response that inhibited biofilm formation in
a foreign body infectionmodel developed in rats (Shahrooei et al.,
2012). Another S. epidermidis recombinant antigen, derived from
Accumulation associated protein (Aap), induced production of
antibodies capable of inhibiting biofilm formation in vitro, and
led to a better control of an implant-originated infection in mice
compared to ovalbumin-vaccinated groups (Yan et al., 2014).
Furthermore, the Major amidase (Atl-AM, a multi-functional
non-covalently cell wall associated protein involved in biofilm
formation) from Staphylococcus induced both Th1 and Th2
response, increased opsonophagocytic killing of S. aureus ex
vivo, reduced pathogen replication in heart, liver, and kidney
and ultimately reduced death of infected mice compared to
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mock-immunized controls (Nair et al., 2015). All these evidences
support the idea that specific components that are relevant for
biofilm production, as vaccine candidates, which merits further
research to determine their safety profiles and efficacy in other
models or the actual host.
MYCOBACTERIAL BIOFILMS AND THE
QUEST FOR NEW VACCINE CANDIDATES
AGAINST TUBERCULOSIS
The relevance of biofilms produced by pathogenic mycobacteria
has recently regained attention, particularly for drug tolerance
(Ojha et al., 2008; Ackart et al., 2014a), where it has been
suggested that persisters found after drug treatment in vivomight
resemble some sort of biofilm (Orme, 2014), and the possible
role of this structure during infection has already been discussed
(Flores Valdez et al., 2014), and it is summarized in Table 1. I
do not mean to say that biofilm must indeed exist during in vivo
infection, only that this mode of growth resemble to some extent
aspects found by Mycobacterium tuberculosis during interaction
with its host.
Most manufacturers grow BCG for vaccine administration to
humans, as a surface pellicle in liquid Sauton medium (Eickhoff,
1977). We have shown that Sauton medium favors formation
of pellicle compared to Middlebrook 7H9 (Flores-Valdez et al.,
2015), and others already demonstrated that pellicle mode of
growth in Sauton medium render BCG more able to persist
within macrophages, induce stronger inflammatory response but
ultimately resulted in less control of bacterial replication in lungs
of aerosol infected C57BL/six mice, after 3 months of infection
with low dose M. tuberculosis H37Rv (Venkataswamy et al.,
2012). Based on these results, it seems rather logical to think that
biofilm mode of growth has not proven to be a useful source of
antigens to protect against pulmonary and latent TB. Conversely,
it suggests it would be worth shifting BCG vaccine production to
Middlebrook 7H9 medium in the presence of detergent to obtain
individual, planktonic cells.
Nevertheless, I think that such a failure to induce protective
immunity by current BCG vaccines produced as biofilms might
be at least partially circumvented if we were able to enhance
biofilm production by BCG or by attenuated strains of M.
tuberculosis. We should definitely first define the key molecular
contributors to biofilm production by mycobacteria with their
expression during in vivo infection. Perhaps current growth
conditions has led to a lack of or suboptimal expression of
relevant antigens from “weak” biofilm-producer BCG strains,
or that under such conditions BCG maintains antigens that
induce very strong but not protective immune response. This
could be linked to a reduced capacity to remain within the
host (or an enhanced clearance due to immune response early
after vaccination), which consequently reduces the opportunity
to express relevant antigens for all stages of infection.
In term of the capacity to remain within the host, we
have recently shown that pellicle production and persistence in
immunocompetent mice are linked in BCG (Flores-Valdez et al.,
2015), and there is evidence that a BCG strain more capable of
producing pellicles protects better than parental BCG against
TB in mice, particularly at 6 months post-infection or upon
reactivation from persistent infection (Pedroza-Roldán et al.,
in preparation). The use of this vaccine candidate in animal
models such as Non-Human Primates (NHP), which more
closely reproduce latent infection, should allow us to determine
whether biofilms share some aspects of this clinically relevant
infection stage.
In the aforementioned study, we did not use bacteria
grown as surface pellicles to immunize mice, so for now we
cannot ascertain whether the BCG vaccine candidate termed
BCG1BCG1419c shows better protection than BCG because it
forms some sort of pellicle in vivo therefore presenting specific
antigens not induced by regular BCG, or because deletion of the
c-di-GMP phosphodiesterase BCG1419c gene render the bacteria
with augmented levels of this second messenger, which has
adjuvant properties (Chen et al., 2010).
New vaccine candidates could result from particular analyses
around the biofilm mode of growth, by taking advantage of
RNA sequencing and bioinformatics (to monitor gene expression
differences during biofilm mode of growth in vitro), real time
qPCR (to seek for correlation between expression of genes
differentially transcribed during biofilm production with that
obtained during in vivo infection), proteomics (to evaluate
correlation between transcription differences and production of
antigenic peptides and proteins relevant for biofilm mode of
growth), immunology (to compare in vivo and/or ex vivo the
cellular and humoral immune response mounted by immunized
subjects/models, toward specific components relevant for biofilm
TABLE 1 | Key recent findings associating biofilms produced by M. tuberculosis-complex bacteria with relevant phenotypes in vitro and in vivo.
Finding References
M. tuberculosis tolerates more antibiotics in vitro within biofilms than as planktonic cells Ojha et al., 2008
M. bovis 1glnA1produces less biofilms, is more susceptible to drugs and is less virulent in BALB/c mice compared to Wt bacteria Chandra et al., 2010
TCA1, a small molecule that inhibits M. tuberculosis biofilms in vitro, reduces bacillary burden in lungs of infected BALB/c mice Wang et al., 2013
Guinea pigs infected with M. tuberculosis produce antibodies against specific proteins present in in vitro grown biofilms Kerns et al., 2014
2-aminoimidazole derivatives that disrupt in vitro grown M. tuberculosis biofilms restore susceptibility to drugs Ackart et al., 2014b
M. tuberculosis 1mmaA4 produces less biofilms and is more susceptible to rifampicin in vitro Sambandan et al., 2013
Leukocyte extracts favors M. tuberculosis biofilm production and drug tolerance ex vivo Ackart et al., 2014a
M. bovis BCG1BCG1419c produces more biofilm in vitro and persists more in lungs and spleens of BALB/c mice Flores-Valdez et al., 2015
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production), and genomics (to determine whether putative
“weak” biofilm producers used for vaccine production differ
in sequences of genes required to control this phenotype).
We should also consider comparing expression of molecules
relevant for biofilm production with that already found
under experimental conditions that have been demonstrated
to occur during in vivo infection, such as hypoxia, reactive
oxygen/nitrogen species stress, nutrient limitation and shift in
carbon source utilization, in order to rule out utilization of
antigens already under study or demonstrated to be poor vaccine
candidates.
I suggest that we should further continue evaluating
the relevance of the biofilm phenotype to produce vaccine
candidates against TB, by following at least one of the next
approaches: (1) genetically engineered, whole cell mycobacteria
with enhanced capacity to produce biofilm and persist longer
in vivo yet displaying a good (attenuated) safety profile, (2)
through the use of specific components produced at different
times during biofilm production, which I recommend be
confirmed to be expressed during in vivo infection, or (3)
via utilization of components exclusively or more abundantly
produced in biofilms than in planktonic cells, and test
them as subunit, perhaps booster vaccines candidates, or (4)
particular components produced at different locations within the
same biofilm, which in other words implies utilizing modern
technologies to map transcriptional diversity depending on
location within the biofilm. Assessment of all or some of these
alternatives should shed light on how successful paying a critical
re-evaluation of biofilms could be against this disease. These
vaccine candidates, perhaps administered using the respiratory
route (which has shown improved control of TB in NHP;
Kaushal et al., 2015; White et al., 2015) when delivery and safety
concerns have been solved, would likely result in better control of
tuberculosis in the near future.
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